PL2295049T3 - Leczenie chorób autoimmunologicznych - Google Patents

Leczenie chorób autoimmunologicznych

Info

Publication number
PL2295049T3
PL2295049T3 PL10174280T PL10174280T PL2295049T3 PL 2295049 T3 PL2295049 T3 PL 2295049T3 PL 10174280 T PL10174280 T PL 10174280T PL 10174280 T PL10174280 T PL 10174280T PL 2295049 T3 PL2295049 T3 PL 2295049T3
Authority
PL
Poland
Prior art keywords
autoimmune diseases
treatment
neuritis
uveitis
invention describes
Prior art date
Application number
PL10174280T
Other languages
English (en)
Inventor
Rainer Albert
Nigel Graham Cooke
Barbara Nuesslein-Hildesheim
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2295049T3 publication Critical patent/PL2295049T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL10174280T 2005-09-09 2006-09-07 Leczenie chorób autoimmunologicznych PL2295049T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09
EP10174280.7A EP2295049B1 (en) 2005-09-09 2006-09-07 Treatment of autoimmune diseases
EP06793341A EP1926483B1 (en) 2005-09-09 2006-09-07 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
PL2295049T3 true PL2295049T3 (pl) 2015-04-30

Family

ID=37056992

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10174280T PL2295049T3 (pl) 2005-09-09 2006-09-07 Leczenie chorób autoimmunologicznych
PL06793341T PL1926483T3 (pl) 2005-09-09 2006-09-07 Leczenie chorób autoimmunologicznych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06793341T PL1926483T3 (pl) 2005-09-09 2006-09-07 Leczenie chorób autoimmunologicznych

Country Status (29)

Country Link
US (1) US20080200438A1 (pl)
EP (2) EP1926483B1 (pl)
JP (4) JP5244598B2 (pl)
KR (3) KR101476591B1 (pl)
CN (1) CN101257899B (pl)
AT (1) ATE489948T1 (pl)
AU (2) AU2006289100B2 (pl)
BR (1) BRPI0615906A2 (pl)
CA (2) CA2820510A1 (pl)
CY (1) CY1111285T1 (pl)
DE (1) DE602006018629D1 (pl)
DK (2) DK1926483T3 (pl)
ES (2) ES2529724T3 (pl)
HK (1) HK1149906A1 (pl)
IL (2) IL189665A (pl)
JO (1) JO2655B1 (pl)
MA (1) MA29787B1 (pl)
MX (1) MX2008003170A (pl)
NO (1) NO20081727L (pl)
NZ (2) NZ566137A (pl)
PL (2) PL2295049T3 (pl)
PT (2) PT2295049E (pl)
RU (2) RU2424795C2 (pl)
SG (1) SG165364A1 (pl)
SI (2) SI2295049T1 (pl)
TN (1) TNSN08103A1 (pl)
TW (2) TWI376223B (pl)
WO (1) WO2007028821A2 (pl)
ZA (1) ZA200801694B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101905023B (zh) * 2004-07-16 2012-07-11 杏林制药株式会社 有效的医药使用方法及与副作用发生的防御相关的方法
US7795472B2 (en) 2004-10-12 2010-09-14 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride and hydrates thereof, and intermediates in the production thereof
US8048928B2 (en) * 2005-10-07 2011-11-01 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for treating liver disease containing 2-amino-1,3-propanediol derivative as active ingredient, and method for treating liver disease
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ574011A (en) * 2006-08-08 2011-10-28 Kyorin Seiyaku Kk Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
SG174029A1 (en) * 2006-08-08 2011-09-29 Kyorin Seiyaku Kk Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
WO2008099781A1 (ja) * 2007-02-13 2008-08-21 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
MY154685A (en) * 2008-05-20 2015-07-15 Kyorin Seiyaku Kk Agent for maintanance of induced remission
MX2011001881A (es) * 2008-08-18 2011-05-30 Novartis Ag Derivados de amino-alcohol para el tratamiento de neuropatias perifericas desmielinizantes.
JP2013530937A (ja) * 2010-05-06 2013-08-01 ノバルティス アーゲー 自己免疫疾患の処置剤
CN102917698A (zh) * 2010-05-06 2013-02-06 诺瓦提斯公司 二芳基硫醚衍生物的给药方案

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
EP2030614A1 (en) * 1997-02-27 2009-03-04 Novartis AG Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin
EP1431284B1 (en) * 2001-09-27 2007-11-21 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
ATE463478T1 (de) * 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
AU2003264430B2 (en) * 2002-09-19 2009-03-19 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
US20060046979A1 (en) * 2002-09-24 2006-03-02 Foster Carolyn A Organic compounds
EP1545472B1 (en) * 2002-09-28 2010-12-08 McNeil-PPC, Inc. Modified release dosage forms with two cores and an opening
BRPI0407658A (pt) * 2003-02-18 2006-02-21 Kyorin Seiyaku Kk derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico
DE122011100047I1 (de) * 2003-04-08 2011-12-15 Mitsubishi Tanabe Pharma Corp Feste pharmazeutische darreichungsformen mit einemS1P rezeptoragonisten und einem zuckeralkohol.
TW200505416A (en) * 2003-08-12 2005-02-16 Mitsubishi Pharma Corp Bi-aryl compound having immunosuppressive activity
AU2004268052B2 (en) * 2003-08-28 2009-11-19 Novartis Ag Aminopropanol derivatives
CN101905023B (zh) * 2004-07-16 2012-07-11 杏林制药株式会社 有效的医药使用方法及与副作用发生的防御相关的方法
EP2359821A1 (en) * 2004-11-29 2011-08-24 Novartis AG Dosage regimen of an s1p receptor agonist
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
SI1926483T1 (sl) 2011-04-29
AU2006289100A1 (en) 2007-03-15
CN101257899B (zh) 2012-10-03
DE602006018629D1 (de) 2011-01-13
EP1926483A2 (en) 2008-06-04
JP2009507810A (ja) 2009-02-26
TW200803829A (en) 2008-01-16
SG165364A1 (en) 2010-10-28
EP1926483B1 (en) 2010-12-01
EP2295049A1 (en) 2011-03-16
JP5244598B2 (ja) 2013-07-24
AU2010224355B2 (en) 2012-03-29
TWI372620B (en) 2012-09-21
IL233328A0 (en) 2014-08-31
DK1926483T3 (da) 2011-03-14
JP6077265B2 (ja) 2017-02-08
RU2493840C2 (ru) 2013-09-27
KR20140019033A (ko) 2014-02-13
EP2295049B1 (en) 2014-11-26
DK2295049T3 (en) 2015-02-23
NZ566137A (en) 2011-05-27
ZA200801694B (en) 2009-09-30
JP2017019854A (ja) 2017-01-26
KR101476451B1 (ko) 2014-12-24
KR20140117704A (ko) 2014-10-07
RU2008113187A (ru) 2009-10-20
CA2620554C (en) 2013-12-17
HK1149906A1 (en) 2011-10-21
NO20081727L (no) 2008-06-06
WO2007028821A2 (en) 2007-03-15
NZ588372A (en) 2012-03-30
RU2424795C2 (ru) 2011-07-27
CA2620554A1 (en) 2007-03-15
JP2015025002A (ja) 2015-02-05
PL1926483T3 (pl) 2011-05-31
ATE489948T1 (de) 2010-12-15
IL189665A (en) 2014-07-31
TWI376223B (en) 2012-11-11
WO2007028821A3 (en) 2007-05-03
AU2006289100B2 (en) 2010-07-22
CA2820510A1 (en) 2007-03-15
AU2010224355A1 (en) 2010-10-14
MA29787B1 (fr) 2008-09-01
CN101257899A (zh) 2008-09-03
PT1926483E (pt) 2011-03-03
PT2295049E (pt) 2015-03-02
JP2013010802A (ja) 2013-01-17
JO2655B1 (en) 2012-06-17
RU2011111117A (ru) 2012-09-27
BRPI0615906A2 (pt) 2011-05-31
KR101476591B1 (ko) 2014-12-24
US20080200438A1 (en) 2008-08-21
ES2529724T3 (es) 2015-02-25
TNSN08103A1 (en) 2009-07-14
MX2008003170A (es) 2008-03-18
TW201034659A (en) 2010-10-01
IL189665A0 (en) 2008-06-05
CY1111285T1 (el) 2015-08-05
ES2357426T3 (es) 2011-04-26
SI2295049T1 (sl) 2015-03-31
KR20080046231A (ko) 2008-05-26

Similar Documents

Publication Publication Date Title
TWI372620B (en) Treatment of autoimmune diseases
TW200509892A (en) Novel aminobenzophenone compounds
EP1841426A4 (en) TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP1673078A4 (en) BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
WO2006058868A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
PL1910338T3 (pl) Związki heterotetracykliczne jako mimetyki TPO
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
TW200806325A (en) Therapeutic uses of inhibitors of RTP801
MX2008002166A (es) Compuestos y composiciones como mimeticos de trombopoietina (tpo).
TW200635597A (en) Substituted pteridines for the treatment of inflammatory diseases
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
TW200633711A (en) Substituted pteridines for the treatment of inflammatory diseases
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
WO2007019080A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
IL181713A0 (en) Use of il-17f for the treatment and/or prevention of neurological diseases
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
TW200505435A (en) Treatment of ocular disorders
CY1116051T1 (el) Θεραπεια αυτοανοσων ασθενειων
TW200628453A (en) Triazole substituted aminobenzophenone compounds
BRPI0402756A (pt) método para o tratamento de distúrbios cognitivos